Osimertinib

Introduction Overview

Generic Name

osimertinib

Brand Name

Tagrisso

Dosage Form

oral tablet (40 mg; 80 mg)

Drug Class

EGFR inhibitors

Pharmacokinetics

Absorption: Osimertinib exhibits good oral bioavailability when administered as a tablet, with peak plasma concentrations typically reached within 6 hours after dosing. Food does not significantly affect its absorption, allowing administration with or without meals. The compound demonstrates dose-proportional pharmacokinetics within the therapeutic range. Extensive studies have confirmed that its absorption is consistent and reliable, facilitating once-daily dosing.

Distribution: After absorption, osimertinib exhibits a large apparent volume of distribution, indicating extensive tissue distribution. It is highly protein-bound (approximately 95%) primarily to albumin and alpha-1 acid glycoprotein. Osimertinib has good penetration into tumor tissues and the central nervous system, including the brain, which is clinically significant for treating metastatic non-small cell lung cancer (NSCLC) with brain involvement.

Metabolism: Osimertinib is primarily metabolized in the liver by cytochrome P450 enzymes, especially CYP3A4 and CYP3A5, through oxidative pathways. The drug undergoes oxidative N-demethylation and other phase I reactions forming active metabolites. Its metabolism is subject to inter-individual variability influenced by genetic polymorphisms and concomitant drugs that inhibit or induce CYP3A enzymes. The active metabolites contribute to the overall pharmacologic effect but are generally less potent than the parent compound.

Elimination: Osimertinib and its metabolites are eliminated predominantly via the feces (approximately 68%), with less than 14% excreted in the urine. The terminal elimination half-life averages around 48 hours, supporting once-daily dosing schedules. Clearance is mainly via hepatic metabolism, and the drug's elimination is not significantly affected by mild to moderate renal impairment, although severe hepatic impairment may alter pharmacokinetics. Clinical pharmacokinetic studies support steady-state attainment within 15 days of continuous dosing.

Dosage Forms

Available Dosage Forms: Osimertinib is formulated as oral tablets available in strengths of 40 mg and 80 mg. These tablets are designed for once-daily oral administration and can be swallowed whole or dispersed in water to facilitate swallowing.

Dosages for Adults and Adolescents: The recommended adult dose for treating EGFR mutation-positive non-small cell lung cancer (NSCLC) is 80 mg orally once daily. This dose applies in multiple clinical settings including adjuvant therapy post-tumor resection, first-line therapy for metastatic NSCLC, and treatment of metastatic T790M mutation-positive NSCLC after progression on prior EGFR tyrosine kinase inhibitors.

Specific Patient Populations: Dose adjustments are generally not required for patients with mild to moderate hepatic impairment or mild to severe renal impairment; however, close monitoring is advised. Osimertinib is contraindicated during pregnancy due to potential teratogenicity and fetal harm. Breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. There is limited safety data in pediatric populations; thus, osimertinib use is primarily restricted to adult patients. For patients with swallowing difficulties, tablets can be dispersed in water as an alternative administration method.

Mechanism Of Action

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to irreversibly bind to mutant forms of the EGFR receptor that drive oncogenesis in certain non-small cell lung cancers. It selectively targets both sensitizing EGFR mutations such as exon 19 deletions and L858R mutations on exon 21, as well as the T790M resistance mutation that commonly emerges after initial EGFR-targeted therapies.

Molecularly, osimertinib covalently binds to cysteine-797 in the ATP-binding site of the mutant EGFR kinase domain, thereby irreversibly inhibiting its tyrosine kinase activity. This blockade prevents phosphorylation and downstream signaling pathways including the PI3K/AKT and MAPK/ERK cascades, which are essential for cancer cell proliferation, survival, angiogenesis, and metastasis.

At the cellular level, osimertinib induces apoptosis and cell cycle arrest in tumor cells harboring the relevant EGFR mutations, leading to decreased tumor growth and potential tumor regression. Its high selectivity for mutant EGFR spares wild-type EGFR, thereby reducing toxicity associated with earlier EGFR inhibitors.

Clinically, osimertinib’s ability to cross the blood-brain barrier allows effective treatment of central nervous system metastases, a frequent site of progression in NSCLC. Comparative studies demonstrate osimertinib’s superiority in progression-free survival and tolerability over earlier generation EGFR TKIs, making it a front-line and post-resistance therapeutic standard. Current research continues to explore osimertinib in combination regimens and for other EGFR-driven malignancies.

Pharmacological Actions

Selective and irreversible inhibition of mutant EGFR tyrosine kinase, including T790M resistance mutation
Inhibition of tumor cell proliferation via blockade of EGFR-mediated signaling pathways
Induction of apoptosis in EGFR mutation-positive cancer cells
Crosses the blood-brain barrier to treat brain metastases effectively
Demonstrates higher specificity for mutant EGFR than wild-type receptor, reducing adverse effects
Provides targeted therapy for NSCLC with minimal impact on normal cells
Overcomes resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Sustains suppression of EGFR signaling leading to prolonged disease control
Modulates downstream PI3K/AKT and MAPK pathways critical for tumor survival
Exhibits a long half-life enabling once-daily oral dosing
Active metabolites contribute to the overall antineoplastic activity
Improves progression-free and overall survival in clinical trials
Reduces tumor burden and delays disease progression in advanced NSCLC
Potentially modulates tumor microenvironment by inhibiting growth factor signaling
Effective in both adjuvant and metastatic settings for EGFR-mutated NSCLC

Therapeutic Or Clinical Uses

First-line treatment for metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations
Adjuvant therapy post-surgical resection for NSCLC patients harboring specific EGFR mutations to reduce recurrence risk
Treatment of metastatic EGFR T790M mutation-positive NSCLC after progression on prior EGFR tyrosine kinase inhibitor therapy
Management of NSCLC with brain metastases due to its CNS penetration capabilities
Therapy for patients with EGFR mutation-positive NSCLC unsuitable for chemotherapy
Use in patients with acquired resistance to earlier generation EGFR inhibitors
Potential investigational use in other EGFR-mutated tumors under clinical trials
Improvement of progression-free survival and quality of life in advanced NSCLC
Reduction of tumor size and symptom control in EGFR mutation-driven lung cancers
Treatment option for patients with multiple lines of therapy failure
Part of combination regimens in ongoing research for enhanced antitumor efficacy
Maintenance therapy to delay disease progression after initial response
Option for patients with comorbidities precluding cytotoxic chemotherapy
Tailored targeted therapy based on molecular genetic testing for personalized oncology care
Oral therapy facilitating outpatient treatment and ease of administration

Side Or Adverse Effects

Low blood cell counts leading to anemia, neutropenia, or thrombocytopenia
Muscle, bone, or joint pain (myalgia, arthralgia)
Diarrhea, which can range from mild to severe
Fatigue and tiredness impacting daily activities
Persistent cough and respiratory symptoms
Mouth sores or stomatitis causing discomfort
Dry skin and various dermatologic reactions including rash
Nail disorders such as redness, tenderness, pain, or inflammation around fingernails and toenails
Serious skin reactions including blistering, peeling, or rash suggestive of Stevens-Johnson syndrome
Cardiac side effects including palpitations, fast or irregular heartbeats, and potential QT prolongation
Pulmonary toxicity manifesting as worsening cough, shortness of breath, or pneumonitis
Ocular toxicities such as vision changes, eye pain, redness, and increased photosensitivity
Fluid retention with swelling in lower extremities and rapid weight gain
Light-headedness or syncope related to cardiovascular effects
Increased susceptibility to infections due to immunosuppression

Precautions

Monitor for cardiac function regularly due to risk of QT prolongation and arrhythmias
Assess baseline and periodic blood counts to detect hematologic toxicity early
Use with caution in patients with pre-existing lung or breathing problems
Evaluate and correct electrolyte imbalances prior to and during therapy
Advise against pregnancy and enforce effective contraception for both men and women during and after treatment
Avoid breastfeeding during treatment and for at least 2 weeks after the last dose due to potential drug excretion in milk
Monitor for early signs of interstitial lung disease or pneumonitis
Screen for and manage skin toxicity promptly to avoid progression to severe reactions
Closely monitor symptoms suggestive of infection given immunosuppressive effects
Use caution in patients with pre-existing eye disorders; conduct regular ophthalmologic assessments
Adjust therapy or discontinue if severe adverse reactions or toxicity occurs
Avoid concomitant use with strong CYP3A4 inducers or inhibitors without medical supervision
Counsel patients on adherence and on how to manage missed doses safely
Store medication at room temperature, protected from moisture and heat
Be cautious in elderly patients who may have altered pharmacokinetics and increased susceptibility to adverse effects

Warnings

May cause serious heart problems including QT interval prolongation, arrhythmias, and congestive heart failure
Risk of severe and potentially fatal interstitial lung disease or pneumonitis
Can induce life-threatening skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis
Potential for severe hematologic toxicities with low blood cell counts leading to infection, bleeding, and anemia
Risks of ocular adverse effects including vision changes and eye pain; immediate evaluation required if symptoms occur
Osimertinib can cause fetal harm; contraindicated during pregnancy and requires effective contraception
May induce fluid retention leading to edema and cardiac stress
Treatment may need to be delayed, interrupted, or discontinued based on severity of adverse reactions
Patients should be advised to report any new or worsening cardiac, pulmonary, skin, or ocular symptoms promptly
Avoid use in patients with known hypersensitivity to osimertinib or its components
Close monitoring advised when used concomitantly with other QT-prolonging drugs
Potential drug interactions may increase toxicity; comprehensive medication review is essential
Safety and efficacy have not been established in pediatric populations
Use caution in patients with liver or kidney impairment due to altered drug elimination
May impair ability to perform tasks requiring alertness due to fatigue or other side effects

Contraindication

Known hypersensitivity or allergy to osimertinib or any of its excipients
Pregnancy due to potential teratogenic effects and fetal harm
Breastfeeding mothers during drug therapy and for at least two weeks after the final dose
Concurrent use with drugs that are strong CYP3A inducers without medical supervision due to risk of reduced efficacy
Patients with uncontrolled cardiac conditions, especially those predisposing to QT prolongation, unless benefits outweigh risks
Severe hepatic impairment without close clinical monitoring
Patients who have experienced severe cutaneous adverse reactions to prior EGFR inhibitors
Patients unable to comply with contraceptive requirements for childbearing potential
Known or suspected cases of interstitial lung disease or pneumonitis exacerbated by EGFR-TKI therapy
Use in pediatric patients due to lack of safety and efficacy data
Patients with active infections or immunocompromised status unless adequately managed
Use with caution in patients with electrolyte imbalances uncorrected prior to therapy

Drug Interactions

Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease osimertinib plasma levels and reduce efficacy
Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase osimertinib plasma concentrations leading to toxicity
Concurrent use with other QT-prolonging agents (e.g., certain antiarrhythmics, antipsychotics) increases risk of cardiac arrhythmias
Caution when used with drugs metabolized by CYP3A due to potential competition or altered metabolism
Possible interactions with drugs affecting electrolyte balance (e.g., diuretics, laxatives) increasing risk of cardiac adverse effects
Drugs affecting P-glycoprotein transporter may alter osimertinib absorption or clearance
Co-administration with immunosuppressants may increase infection risk during treatment
Use caution with herbal supplements such as St. John's Wort that induce CYP3A enzymes
Interactions with proton pump inhibitors or acid-reducing agents are minimal but monitoring is advised
Potential interaction with warfarin or other anticoagulants may alter bleeding risk
Avoid concomitant use with other EGFR-targeting therapies unless under strict clinical supervision
Interactions with antiretroviral drugs may necessitate dose adjustment or monitoring
Concomitant use with corticosteroids may modify osimertinib adverse effect profile
Drug interaction with certain antidepressants affecting cardiac conduction requires monitoring
Comprehensive medication review is recommended before starting osimertinib therapy

Preparations Of The Drug

Osimertinib is available as oral tablets suitable for once-daily administration
Tablets are provided in 40 mg and 80 mg strengths
Formulation designed for effective systemic exposure and CNS penetration
Packaging typically includes blister packs or bottles containing a designated number of tablets
Storage at controlled room temperature, protected from moisture and heat
Tablets may be dispersed in water to facilitate swallowing for patients with dysphagia
No intravenous or topical formulations currently available
No combination formulations with other anticancer agents are commercially available
Manufactured under stringent quality control to ensure consistent dosing and purity
Available through prescription only, specialized oncology pharmacies typically provide the drug
Special handling requirements include safe disposal of unused medication due to cytotoxic potential
Patient information leaflets include detailed directions for administration and precautions
Product undergoes regular regulatory review for safety and efficacy post-marketing
Generic forms are available in some markets, maintaining bioequivalence to the branded tablet
Packaging includes tamper-evident seals and child-resistant containers to ensure safety